Apatinib in combination with gefitinib in the first-line setting demonstrated superior progression-free survival (PFS) in patients with advanced EGFR-mutant non–small cell lung cancer.
Patients with triple-negative breast cancer experienced improved pathologic complete responses with the addition of neoadjuvant atezolizumab to chemotherapy.
The PARP inhibitor reduced the risk for death by 31% in men with metastatic castration-resistant prostate cancer, compared with enzalutamide or abiraterone plus prednisone.
First-line treatment with the third-generation ALK TKI was also associated with higher overall and intracranial response rates in patients with ALK-positive non–small cell lung cancer.
“Dostarlimab demonstrated durable antitumor activity in both dMMR and MMRp advanced and recurrent endometrial cancer,” said Ana Oaknin, MD, PhD.
Sacituzumab govitecan-hziy induced significant activity with favorable tolerability in heavily pretreated patients with metastatic urothelial carcinoma.